Implementation Report. Within 120 days after the Effective Date, KDMC shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include: 1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have; 2. the names and positions of the members of the Compliance Committee required by Section III.A.2; 3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3; 4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have; 5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have; 6. a copy of KDMC’s Code of Conduct required by Section III.B.1; 7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request); 8. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request); 9. the following information regarding each type of training required by Section III.C: a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request. 10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 11. a description of the Disclosure Program required by Section III.G;
Appears in 2 contracts
Sources: Corporate Integrity Agreement, Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC Progenity shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, business address, business phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, III.A.4 and a summary copy of other job responsibilities that each Physician Executive may havethe written process for Certifying Employees to follow in order to complete the certification required by Section III.A.4;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s Code of Conduct required by Section III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
8. a summary list of all Policies and Procedures required by Section III.B.2 (copies III.B;
6. the Training Plan required by Section III.C.1 and a description of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type of Board training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessionsthe training, and a schedule of when the training sessions; andwas provided);
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
107. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.aIII.D.1.a, (b) the internal review and approval process required by Section III.F.1.eIII.D.1.g; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1III.D.1;
8. the following information regarding the IRO(s): (a) identity, address, and phone number; 11(b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; and (d) a certification from the IRO regarding its professional independence and objectivity with respect to Progenity or that it does not have a prohibited relationship with Progenity as set forth in Section III.E.4, that includes a summary of all current and prior engagements or relationships between Progenity and the IRO, as applicable;
9. a description of the risk assessment and internal review process required by Section III.F; 10. a description of the Disclosure Program required by Section III.G; 11. a description of the Ineligible Persons screening and removal process required by Section III.H;
12. a copy of Progenity’s policies and procedures regarding the identification, quantification and repayment of Overpayments required by Section III.J;
Appears in 2 contracts
Sources: Corporate Integrity Agreement (Progenity, Inc.), Corporate Integrity Agreement (Progenity, Inc.)
Implementation Report. Within 120 150 days after the Effective Date, KDMC Halifax shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;
3. the names of the Board members who are responsible for satisfying the Board of Directors Commissioners compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCHalifax’s Code of Conduct required by Section III.B.1;
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy ; and
c. with respect to active medical staff members, the number and percentage who completed the training, the type of all training materials and the documentation supporting this information shall be made available date received, and a description of Halifax’s efforts to OIG upon requestencourage medical staff members to complete the training.
108. a description of of: (a) the Focus Arrangements Tracking System required by Section III.F.1.a, III.D.1.a; (b) the internal review and approval process required by Section III.F.1.eIII.D.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1III.D.1; 119. a description of the Disclosure Program required by Section III.GIII.F;
Appears in 2 contracts
Sources: Corporate Integrity Agreement, Corporate Integrity Agreement
Implementation Report. Within 120 150 days after the Effective Date, KDMC Merit shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include::
1. the name, business address, business phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;;
3. the names of the Board Audit Committee members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, III.A.4 and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s Code of Conduct required by Section III.B.1;
7. the number of individuals required written process for Certifying Employees to follow in order to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);III.A.4;
85. a summary list of all the Policies and Procedures required by Section III.B.2 (copies III.B.1;
6. the Training Plan required by Section III.C.1 and a description of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessions, the training and a schedule of when the training sessionswas provided); and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
107. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the risk assessment and internal review and approval process required by Section III.F.1.eIII.D;
8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; and (cd) a certification from the tracking IRO regarding its professional independence and monitoring procedures objectivity with respect to Merit that includes a summary of all current and other Focus Arrangements Procedures required by Section III.F.1prior engagements between Merit and the IRO; 11
9. a description of the Disclosure Program required by Section III.F;
10. a description of the Ineligible Persons screening and removal process required by Section III.G;
11. a description of policies, procedures, and systems implemented pursuant to the Requirements Relating to Certain Promotional Activities outlined in Section III.K; 12. a description of the FFMP required by Section III.L;
Appears in 1 contract
Sources: Corporate Integrity Agreement (Merit Medical Systems Inc)
Implementation Report. Within 120 150 days after the Effective Date, KDMC CVS Health shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Chief Compliance Officer, the Compliance Officer for IPS Operations, and the Arrangements Officer for IPS Operations required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Chief Compliance Officer, the Compliance Officer for IPS Operations Officer, and the Arrangements Officer for IPS Operations may have;
2. the names and positions of the members of the IPS Operations Compliance Committee and the Compliance Committee required by Section III.A.2III.A.3;
3. the names of the Board members who are members of the Board Committee who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3III.A.4;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may haveIII.A.5;
5. the name, address, phone number, and position description a copy of the Medical Director CVS Health’s Code of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may haveConduct;
6. a copy of KDMC’s Code of Conduct required by Section III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type Training Plan required by Section III.C.1 and a description of the Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessionsthe training, and a schedule of when the training sessionswas provided); and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
108. a description of (a) the Focus Arrangements Tracking System Database required by Section III.F.1.aIII.D.1.a, (b) the internal review and approval process required by Section III.F.1.eIII.D.1.g; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1III.D.1; 119. a description of the Disclosure Program Accurate Prescription Drug Labeling and Dispensing Systems and Procedures required by Section III.GIII.E;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 150 days after the Effective Date, KDMC ICH shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may haveIII.A.4;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCICH’s Code of Conduct required by Section III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type Training Plan required by Section III.C.1 and a description of the Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessionsthe training, and a schedule of when the training sessions; andwas provided);
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
108. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.aIII.D.1.a, (b) the internal review and approval process required by Section III.F.1.eIII.D.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1III.D.1;
9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between ICH and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to ICH;
10. a description of the risk assessment and internal review process required by Section III.F; 11. a description of the Disclosure Program required by Section III.G;
12. a certification that ICH has conducted the screening required by Section III.H regarding Ineligible Persons, or a description of why ICH cannot provide such a certification;
13. a copy of ICH’s policies and procedures regarding the identification, quantification and repayment of Overpayments required by Section III.J;
14. a list of all of ICH’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number(s) and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which ICH currently submits claims;
15. a description of ICH’s corporate structure, including identification of any individual owners, parent and sister companies, subsidiaries, and their respective lines of business; and
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 150 days after the Effective Date, KDMC Baptist shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCBaptist’s Code of Conduct required by Section III.B.1;
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and,
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 118. a description of the Disclosure Program required by Section III.GIII.E;
9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between Baptist and the IRO; and, (e) a certification from the IRO regarding its professional independence and objectivity with respect to Baptist; 10. a description of the process by which Baptist fulfills the requirements of Section III.F regarding Ineligible Persons;
11. a list of all of Baptist’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number(s) and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which Baptist currently submits claims;
12. a description of Baptist’s corporate structure and its respective lines of business; and,
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC Toccoa shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;III.A;
3. the names of the Board Executive Committee members who are responsible for satisfying the Board of Directors Executive Committee compliance obligations described in Section III.A.3;III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;III.A.4;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCToccoa’s Code of Conduct required by Section III.B.1;III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);request);
97. the following information regarding each type Training Plan required by Section III.C.1 and a description of the Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessionsthe training; and when the training was provided);
8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a schedule copy of training sessionsthe engagement letter; and
b. (c) information to demonstrate that the number of individuals required IRO has the qualifications outlined in Appendix A to be trained, percentage of individuals actually trained, this CIA; (d) a summary and an explanation description of any exceptions. A copy of and all training materials current and prior engagements and agreements between Toccoa and the documentation supporting this information shall be made available IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to OIG upon request.Toccoa;
109. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the risk assessment and internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 11III.E;
10. a description of the Disclosure Program required by Section III.GIII.F;
11. a certification that Toccoa has implemented the screening requirements described in Section III.G regarding Ineligible Persons, or a description of why Toccoa cannot provide such a certification;
12. a copy of Toccoa’s policies and procedures regarding the identification, quantification and repayment of Overpayments required by Section III.I;
13. a list of all of Toccoa’s locations (including locations and mailing addresses), the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers, each location’s Medicare and state Medicaid program provider number(s) and/or supplier number(s), and the name and address of each Medicare and state Medicaid program contractor to which Toccoa currently submits claims;
14. a description of Toccoa’s corporate structure, including identification of any individual owners, parent and sister companies, subsidiaries, and their respective lines of business; and
15. the certifications required by Section V.C.
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC First Call shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCFirst Call’s Code of Conduct required by Section III.B.1;
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 118. a description of the Disclosure Program required by Section III.GIII.E;
9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between First Call and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to First Call;
10. a description of the process by which First Call fulfills the requirements of Section III.F regarding Ineligible Persons;
11. a list of all of First Call’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number(s) and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which First Call currently submits claims;
12. a description of First Call’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business and any individual owners;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC PRMC shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names and positions of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Physician Executives required by Section III.A.3III.A;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, name and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may haveIII.A;
65. a copy of KDMCPRMC’s Code of Conduct required by Section III.B.1;
6. a copy of all Policies and Procedures required by Section III.B.2;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG OIG, upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions.
c. with respect to active medical staff members, the number and percentage who completed the training, the type of training and the date received, and a description of PRMC’s efforts to encourage medical staff members to complete the training. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 119. a description of the Disclosure Program required by Section III.GIII.F;
10. the following information regarding the IRO(s) and the Peer Review Consultant: (a) identify, address, and phone number; (b) a copy of the engagement letter;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 150 days after the Effective Date, KDMC Aegerion shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described referenced in Section III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, III.A.4 and a summary written copy of other job responsibilities that each Physician Executive may havethe process followed to complete the certification requirements set forth in Section III.A.4;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s Code of Conduct required by Section III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
8. a summary list of all Policies and Procedures required by Section III.B.2 (copies III.B;
6. the Training Plan required by Section III.C.1 and a description of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessions, the training and a schedule of when the training sessions; andwas provided);
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
107. a description of the RAMP required by Section III.D;
8. the following information regarding the IRO(s): (a) the Focus Arrangements Tracking System required by Section III.F.1.aidentity, address, and phone number; (b) a copy of the internal review and approval process required by Section III.F.1.eengagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A; and (cd) a certification from the tracking IRO regarding its professional independence and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 11objectivity with respect to Aegerion;
9. a description of the Disclosure Program required by Section III.F;
10. a description of the Ineligible Persons screening and removal process required by Section III.G;
11. a certification by the Compliance Officer that the notice required by Section III.N was posted in the manner required by Section III.N and a summary of the calls or messages received in response to the notice;
12. a certification from the Compliance Officer that the information regarding Payments and the link to CMS’s Open Payments Data website has been posted on Aegerion’s website as required by Section III.O;
13. a list of all of Aegerion’s U.S-based locations (including locations and mailing addresses); the corresponding name under which each location is doing business; and the location’s Medicare and state Medicaid program provider number and/or supplier number(s) (if applicable);
14. a description of or a table depicting Aegerion’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and
15. the certifications required by Section V.C.
Appears in 1 contract
Sources: Corporate Integrity Agreement (Novelion Therapeutics Inc.)
Implementation Report. Within 120 150 days after the Effective Date, KDMC CHSI shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the The name, address, phone number, and position description of the Corporate Compliance and Privacy Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Corporate Compliance and Privacy Officer may have;have;
2. the name, address, phone number, and position description of each Senior Compliance Director, Corporate Compliance Director, and Facility Compliance Officers required by Section III.A.2, and a summary of other noncompliance job responsibilities each Senior Compliance Director, Corporate Compliance Director, and Facility Compliance officers may have;
3. the names and positions of the members of the Corporate Compliance Work Group required by Section III.A.3;
4. the names and positions of the members of each Facility Compliance Committee required by Section III.A.2;III.A.4;
35. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;III.A.5;
6. a copy of KDMCCHSI’s Code of Conduct required by Section III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);request);
9. the following information regarding each type of training required by Section III.C:III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; andsessions;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. ; and
c. with respect to active medical staff members, the number and percentage who completed the training, the type of training and the date received, and a description of CHSI’s efforts to encourage medical staff members to complete the training. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.aIII.D.1.a, (b) the internal review and approval process required by Section III.F.1.eIII.D.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; III.D.1; 11. a description of the Disclosure Program required by Section III.GIII.F;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC HOTC shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance noncompliance- related job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCHOTC’s Code of Conduct required by Section III.B.1;
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 118. a description of the Disclosure Program required by Section III.GIII.E;
9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between HOTC and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to HOTC; 10. a description of the process by which HOTC fulfills the requirements of Section III.F regarding Ineligible Persons;
11. a list of all of HOTC’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which HOTC currently submits claims;
12. a description of HOTC’s corporate structure, including identification of any HOTC and sister companies, subsidiaries, and their respective lines of business; and
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 150 days after the Effective Date, KDMC Cephalon shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Chief Compliance Officer required by Section III.A.1III.A. 1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;
3. the names (a) a copy of the Board members who are responsible for satisfying letter (including all attachments) required by Sections II.C.6 and III.B.2 sent to each party employing Third Party Personnel; (b) a list of all such existing agreements; and (c) a description of the Board of Directors compliance obligations described in Section III.A.3entities’ response to Cephalon’s letter;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may haveIII.A.4;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCCephalon’s Code of Conduct required by Section III.B.1;
6. to the extent not already provided to the OIG, a copy of all Policies and Procedures required by Section III.B.3;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG OIG, upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request.;
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 119. a description of the Disclosure Program required by Section III.GIII.E;
10. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; and (c) a summary and description of any and all current and prior engagements and agreements between Cephalon and the IRO;
11. a certification from the IRO regarding its professional independence and objectivity with respect to Cephalon;
12. a description of the process by which Cephalon fulfills the requirements of Section III.F regarding Ineligible Persons;
13. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; the actions taken in response to the screening and removal obligations set forth in Section III.F;
14. a list of all of Cephalon’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Federal health care program provider or supplier number(s) (if applicable), and the name and address of each Federal health care program contractor to which Cephalon currently submits claims (if applicable);
15. a description of Cephalon’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business;
16. a certification by the Chief Compliance Officer that the notice required by Section III.L was mailed to each health care provider and entity, the number of health care providers and entities that received a copy of the notice, a sample copy of the notice required by Section III.L, and a summary of the calls and messages received in response to the notice; and
17. the certifications required by Section V.C.
Appears in 1 contract
Implementation Report. Within 120 150 days after the Effective Date, KDMC Merit shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, business address, business phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;
3. the names of the Board Audit Committee members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, III.A.4 and a summary copy of other job responsibilities that each Physician Executive may havethe written process for Certifying Employees to follow in order to complete the certification required by Section III.A.4;
5. the name, address, phone number, and position description a list of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, Policies and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s Code of Conduct Procedures required by Section III.B.1;
76. the number of individuals required to complete the Code of Conduct certification Training Plan required by Section III.B.1, the percentage of individuals who have completed such certification, III.C.1 and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies description of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessions, the training and a schedule of when the training sessions; andwas provided);
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
107. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the risk assessment and internal review and approval process required by Section III.F.1.eIII.D;
8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; and (cd) a certification from the tracking IRO regarding its professional independence and monitoring procedures objectivity with respect to Merit that includes a summary of all current and other Focus Arrangements Procedures required by Section III.F.1prior engagements between Merit and the IRO; 119. a description of the Disclosure Program required by Section III.F; 10. a description of the Ineligible Persons screening and removal process required by Section III.G;
11. a description of policies, procedures, and systems implemented pursuant to the Requirements Relating to Certain Promotional Activities outlined in Section III.K; 12. a description of the FFMP required by Section III.L;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 150 days after the Effective Date, KDMC Par shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;
3. the names of the Board members who are responsible for satisfying of the Board of Directors compliance obligations described referenced in Section III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;III.A.4; Par Corporate Integrity Agreement
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCPar’s Code of Conduct required by Section III.B.1;
76. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG OIG, upon request);
87. a summary of all Policies and Procedures required by Section III.B.2 (copies a copy of the such Policies and Procedures shall be made available to OIG upon request);
98. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. .. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request.
109. a description of the following information regarding the IRO(s): (a) the Focus Arrangements Tracking System required by Section III.F.1.aidentity, address, and phone number; (b) a copy of the internal review and approval process required by Section III.F.1.eengagement letter; and (c) information to demonstrate that the tracking IRO has the qualifications outlined in Appendix A; (d) a summary and monitoring procedures description of any and other Focus Arrangements Procedures required by Section III.F.1all current and prior engagements and agreements between Par and the IRO; 11and (e) a certification from the IRO regarding its professional independence and objectivity with respect to Par; 10. a description of the Disclosure Program required by Section III.GIII.F;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 150 days after the Effective Date, KDMC PharMerica shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (“Implementation Report”). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III. A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names a copy of the Board members who are responsible for satisfying the Board PharMerica’s Code of Directors compliance obligations described Conduct as provided in Section III.A.3III.B.1;
4. the names, addresses, phone numbers, a copy of all Policies and position descriptions of the Physician Executive(s) Procedures required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may haveIII.B.2;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s Code of Conduct required by Section III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG OIG, upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);
96. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, sessions and a schedule of training sessions; and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request.
107. a description of (a) the Focus Arrangements Tracking System Covered Transactions Database required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.eIII.D.1.a; and (c) 8. a description of the tracking and monitoring procedures and other Focus Arrangements Covered Transactions Procedures required by Section III.F.1III.D.1; 119. a description of the Disclosure Program required by Section III.GIII.F;
Appears in 1 contract
Sources: Corporate Integrity Agreement (Safari Holding Corp)
Implementation Report. Within 120 150 days after the Effective Date, KDMC CHSI shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the The name, address, phone number, and position description of the Corporate Compliance and Privacy Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Corporate Compliance and Privacy Officer may have; Community Health Systems, Inc. Corporate Integrity Agreement, Amended
2. the name, address, phone number, and position description of each Senior Compliance Director, Corporate Compliance Director, and Facility Compliance Officers required by Section III.A.2, and a summary of other noncompliance job responsibilities each Senior Compliance Director, Corporate Compliance Director, and Facility Compliance officers may have;
23. the names and positions of the members of the Corporate Compliance Work Group required by Section III.A.3;
4. the names and positions of the members of each Facility Compliance Committee required by Section III.A.2III.A.4;
35. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may haveIII.A.5;
6. a copy of KDMCCHSI’s Code of Conduct required by Section III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions; and
c. with respect to active medical staff members, the number and percentage who completed the training, the type of training Community Health Systems, Inc. Corporate Integrity Agreement, Amended and the date received, and a description of CHSI’s efforts to encourage medical staff members to complete the training. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.aIII.D.1.a, (b) the internal review and approval process required by Section III.F.1.eIII.D.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1III.D.1; 11. a description of the Disclosure Program required by Section III.GIII.F;
Appears in 1 contract
Sources: Corporate Integrity Agreement (Community Health Systems Inc)
Implementation Report. Within 120 days after the Effective Date, KDMC Lundbeck shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;III.A.2;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, III.A.4 and a summary written copy of other job responsibilities that each Physician Executive may have;the process to be followed by Certifying Employees in connection with completing the required certifications;
5. the name, address, phone number, and position description a list of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s Code of Conduct required by Section III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies III.B.3;
6. the Training Plan required by Section III.C.1 and a description of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessions, the training and a schedule of when the training sessions; andwas provided);
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
10. a description of (a) a copy of the Focus Arrangements Tracking System letter (including all attachments) required by Section III.F.1.a, III.C.4 sent to each party employing Third Party Personnel; (b) a list of all existing co-promotion and other applicable agreements with the internal review and approval process required by Section III.F.1.eparty employing the Third Party Personnel; and (c) description of the tracking entities’ response to Lundbeck’s letter;
8. a description of the risk assessment and monitoring procedures and other Focus Arrangements Procedures internal review process required by Section III.F.1III.D;
9. the following information regarding the IRO(s): (a) identity, address, and phone number; 11(b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A; and (d) a certification from the IRO regarding its professional independence and objectivity with respect to Lundbeck;
10. a description of the Disclosure Program required by Section III.G;III.F; 11. a description of the Ineligible Persons screening and removal process required by Section III.G.; 12. a description of the Independent Charity PAP policies, procedures, and practices required by Section III.J;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC the DIG Entities shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members Directors who are responsible for satisfying the Board of Directors Directors’ compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s the DIG Entities’ Code of Conduct required by Section III.B.1;
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
108. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.aIII.D.1.a, (b) the internal review and approval process required by Section III.F.1.eIII.D.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1III.D.1; 119. a description of the Disclosure Program required by Section III.GIII.F;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 150 days after the Effective Date, KDMC IHS shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may haveIII.A.4;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCIHS’s Code of Conduct required by Section III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type Training Plan for General and Arrangements Training required by Section III.C.1 and a description of the Board of Directors training required by Section III.C:III.C.2;
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
108. a description of of: (a) the Focus Arrangements Tracking System required by Section III.F.1.a, III.D.1.a; (b) the internal review and approval process required by Section III.F.1.eIII.D.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1III.D.1;
9. the following information regarding the Legal IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the Legal IRO has the qualifications outlined in Appendix A to this CIA; and (d) a certification from the Legal IRO that it does not have a prohibited relationship to IHS as set forth in Section III.E.4;
10. a description of the risk assessment and mitigation process required by Section III.F; 11. a description of the Disclosure Program required by Section III.G;
12. a certification that IHS has conducted the screening required by Section III.H regarding Ineligible Persons;
13. a copy of IHS’s policies and procedures regarding the identification, quantification, and repayment of Overpayments required by Section III.J;
14. a list of all of IHS’s locations subject to the CIA (including physical locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number(s) and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which IHS currently submits claims;
15. a description of IHS’s corporate structure, including identification of any owners, parent and sister companies, subsidiaries, and their respective lines of business; and
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC SpecialCare shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;
3. the names and position descriptions of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Certifying Employees required by Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCSpecialCare’s Code of Conduct required by Section III.B.1;
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
108. a description of of: (a) the Focus Arrangements Tracking System required by Section III.F.1.a, III.D.1.a; (b) the internal review and approval process required by Section III.F.1.eIII.D.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1III.D.1; 119. a description of the Disclosure Program required by Section III.GIII.F;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC DaVita shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Chief Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Chief Compliance Officer may have;
2. the names and positions of the members of the Management Compliance Committee required by Section III.A.2;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCDaVita Dialysis’s Code of Conduct required by Section III.B.1;
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary copies of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request)III.B.2;
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
10. DaVita HealthCare Partners Inc. Corporate Integrity Agreement 8. a description of of: (a) the Selection Process and Selection Criteria required by Section III.D.1; (b) the Valuation Methodologies required by Section III.D.2; (c) the Focus Arrangements Tracking System required by Section III.F.1.a, III.D.3.a; (bd) the internal review and approval process required by Section III.F.1.eIII.D.3.f; and (ce) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 11. a description of the Disclosure Program required by Section III.GIII.D.3;
Appears in 1 contract
Sources: Corporate Integrity Agreement (Davita Healthcare Partners Inc.)
Implementation Report. Within 120 days after the Effective Date, KDMC ▇▇▇▇▇▇▇▇ shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s ▇▇▇▇▇▇▇▇’▇ Code of Conduct required by Section III.B.1;
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
108. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.aIII.D.1.a, (b) the internal review and approval process required by Section III.F.1.eIII.D.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1III.D.1; 119. a description of the Disclosure Program required by Section III.GIII.F;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 180 days after the Effective Date, KDMC Mallinckrodt shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, III.A.4 and a summary written copy of other job responsibilities that each Physician Executive may havethe process to be followed by Certifying Employees in connection with completing the required certifications;
5. the name, address, phone number, and position description a list of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, Policies and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s Code of Conduct Procedures required by Section III.B.1;
76. the number of individuals required to complete the Code of Conduct certification Training Plan required by Section III.B.1, the percentage of individuals who have completed such certification, III.C.1 and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies description of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessions, the training and a schedule of when the training sessions; andwas provided);
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
107. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the risk assessment and internal review and approval process required by Section III.F.1.eIII.D;
8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; and (cd) a certification from the tracking IRO regarding its professional independence and monitoring procedures objectivity with respect to Mallinckrodt that includes a summary of all current and other Focus Arrangements Procedures required by Section III.F.1prior engagements between Mallinckrodt and the IRO; 119. a description of the Disclosure Program required by Section III.GIII.F; 10. a description of the Ineligible Persons screening and removal process required by Section III.G.;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC Odyssey Hospice shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCParent’s Code of Business Ethics and Conduct required by Section III.B.1;
74. the number of individuals required to complete the Code of Business Ethics and Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
85. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);): Odyssey Corporate Integrity Agreement
96. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 117. a description of the Disclosure Program required by Section III.GIII.E;
8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between Odyssey Hospice or Parent and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to Odyssey Hospice and Parent;
9. a description of the process by which Odyssey Hospice fulfills the requirements of Section III.F regarding Ineligible Persons;
10. a list of all of Odyssey Hospice’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which Odyssey Hospice currently submits claims;
11. a description of Odyssey Hospice’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and Odyssey Corporate Integrity Agreement
12. the certifications required by Section V.C.
Appears in 1 contract
Sources: Corporate Integrity Agreement (Gentiva Health Services Inc)
Implementation Report. Within 120 150 days after the Effective Date, KDMC Jazz shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCJazz’s Code of Conduct required by Section III.B.1;
74. a copy of all Policies and Procedures required by Section III.B.2;
5. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG OIG, upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);
96. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, sessions and a schedule of training sessions; and;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.aCorporate Integrity Agreement Jazz Pharmaceuticals, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 11Inc. 7. a description of the Disclosure Program required by Section III.GIII.E;
8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; and (c) a summary and description of any and all current and prior engagements and agreements between Jazz and the IRO; and the proposed start and completion dates of each Review;
9. a certification from the IRO regarding its professional independence and objectivity with respect to Jazz; 10. a description of the process by which Jazz fulfills the requirements of Section III.F regarding Ineligible Persons;
Appears in 1 contract
Sources: Corporate Integrity Agreement (Jazz Pharmaceuticals Inc)
Implementation Report. Within 120 days after the Effective Date, KDMC UHS shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Audit Committee of the Board of Directors compliance obligations described in Section III.A.3III.A;
4. the names, addresses, phone numbers, and position descriptions a description of the Physician Executive(s) Quality of Care Review Program required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may haveIII.A.2;
5. the name, address, phone number, and position a description of the Medical Director of the Cardiac Catheterization Laboratory Dashboard required by Section III.A.7, and a summary of other job responsibilities the Medical Director may haveIII.A.2;
6. the names and positions of the Certifying Employees required by Section III.A.4 and a copy of KDMC’s Code of Conduct the written process for completing the certification required by Section III.B.1III.A.4;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
8. a summary list of all Policies and Procedures required by Section III.B.2 (copies III.B;
8. the Training Plan required by Section III.C.1 and a description of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessionsthe training, and a schedule of when the training sessions; andwas provided);
b. 9. the number of individuals required to be trainedfollowing information regarding the IRO(s): (a) identity, percentage of individuals actually trainedaddress, and an explanation of any exceptions. A phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; and (d) a certification from the IRO regarding its professional independence and objectivity with respect to UHS that includes a summary of all training materials current and prior engagements between UHS and the documentation supporting this information shall be made available to OIG upon request.IRO;
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the risk assessment and internal review and approval process required by Section III.F.1.eIII.F; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 11. a 11.a description of the Disclosure Program required by Section III.G;
Appears in 1 contract
Sources: Corporate Integrity Agreement (Universal Health Services Inc)
Implementation Report. Within 120 days after the Effective Date, KDMC CHN shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may haveIII.A.4;
5. the name, address, phone number, and position description a copy of the Medical Director of the Cardiac Catheterization Laboratory written process for Certifying Employees required by Section III.A.7, and a summary of other job responsibilities the Medical Director may haveIII.A.4;
6. a copy of KDMCCHN’s Code of Conduct required by Section III.B.1;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
98. the following information regarding each type Training Plan required by Section III.C.1 and a description of the Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessionsthe training; and when the training was provided);
9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a schedule copy of training sessionsthe engagement letter; and
b. (c) information to demonstrate that the number of individuals required IRO has the qualifications outlined in Appendix A to be trained, percentage of individuals actually trained, this CIA; (d) a summary and an explanation description of any exceptions. A copy of and all training materials current and prior engagements and agreements between CHN and the documentation supporting this information shall be made available IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to OIG upon request.CHN;
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the risk assessment and internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1III.E; 11. a description of the Disclosure Program required by Section III.GIII.F;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 150 days after the Effective Date, KDMC Avanir shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may have;have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;III.A.2;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, III.A.4 and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s Code of Conduct required the written process to be followed by Section III.B.1;
7. Certifying Employees in connection with completing the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);III.A.4;
85. a summary list of all the Policies and Procedures required by Section III.B.2 (copies III.B.3;
6. the Training Plan required by Section III.C.1 and a description of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type Board of Directors training required by Section III.C:
a. a description of such training, III.C.2 (including a summary of the topics covered, the length of sessions, the training and a schedule of when the training sessions; andwas provided);
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
107. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review risk assessment and approval mitigation plan process required by Section III.F.1.eIII.D;
8. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; and (cd) a certification from the tracking IRO regarding its professional independence and monitoring procedures objectivity with respect to Avanir that includes a summary of all current and other Focus Arrangements Procedures required by Section III.F.1prior engagements between ▇▇▇▇▇▇ and the IRO; 119. a description of the Disclosure Program required by Section III.G;III.F; 10. a description of the Ineligible Persons screening and removal process required by Section III.G;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC EGS shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCEGS’s Code of Conduct required by Section III.B.1;
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. ; A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.;
108. a description of (a) the Focus Arrangements Tracking System Risk Assessment and Mitigation Process required by Section III.F.1.a, III.E (b) if applicable);
9. a description of the internal review and approval process Field Force Monitoring Program required by Section III.F.1.eIII.F; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 1110. a description of the Disclosure Program required by Section III.GIII.H;
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 180 days after the Effective Date, KDMC Allergan shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Chief Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Chief Compliance Officer may have;
2. the names and positions of the members of the U.S. Compliance Committee required by Section III.A.2;
3. the names of the Board members who are responsible for satisfying of the full Board of Directors and any Committee of the Board with responsibility for compliance obligations described as referenced in Section III.A.3;
4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may haveIII.A.4;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCAllergan’s Code of Conduct required by Section III.B.1;
76. the number of individuals Covered Persons required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals Covered Persons who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG OIG, upon request);
7. a) a copy of the letter (including all attachments) required by Section II.C.6 and III.B.2 sent to each party employing Third Party Personnel; b) a list of all such existing co-promotion and other applicable agreements; and c) a description of the entities’ response to Allergan’s letter;
8. a summary of all Policies and Procedures required by Section III.B.2 III.B.3 (copies a copy of the such Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and
b. the number of individuals Covered Persons required to be trained, percentage of individuals Covered Persons actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request.;
10. a description of the following information regarding the IRO(s): (a) the Focus Arrangements Tracking System required by Section III.F.1.aidentity, address, and phone number; (b) a copy of the internal review and approval process required by Section III.F.1.eengagement letter; and (c) a summary and description of any and all current and prior engagements and agreements between Allergan and the tracking IRO;
11. a certification from the IRO regarding its professional independence and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1objectivity with respect to Allergan; 1112. a description of the Disclosure Program required by Section III.GIII.E;
13. a description of the process by which Allergan fulfills the requirements of Section III.F regarding Ineligible Persons;
14. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; the actions taken in response to the screening and removal obligations set forth in Section III.F;
15. a certification by the Chief Compliance Officer that the notice required by Section III.L was mailed to each HCP and HCI, the number of HCPs and HCIs that received a copy of the notice, a sample copy of the notice required by Section III.L, and a summary of the calls or messages received in response to the notice;
16. a list of all of Allergan’s U.S. locations (including locations and mailing addresses); the corresponding name under which each location is doing business; and the corresponding phone numbers and fax numbers;
17. a description of Allergan’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and
Appears in 1 contract
Implementation Report. Within 120 days after the Effective Date, KDMC LWCI shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCLWCI’s Code of Conduct required by Section III.B.1;
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions; and
c. with respect to active medical staff members, the number and percentage who completed the training, the type of training and the date received, and a description of LWCI’s efforts to encourage medical staff members to complete the training. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 118. a description of the Disclosure Program required by Section III.GIII.E;
9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between LWCI and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to LWCI;
10. a description of the process by which LWCI fulfills the requirements of Section III.F regarding Ineligible Persons;
11. a list of all of LWCI’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name and address of each Medicare and state Medicaid program contractor to which LWCI currently submits claims;
12. a description of LWCI’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business;and
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 days after the Effective Date, KDMC ▇▇▇▇▇▇▇▇▇▇ Regional shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC▇▇▇▇▇▇▇▇▇▇ Regional’s Code of Conduct required by Section III.B.1;; ▇▇▇▇▇▇▇▇▇▇ Regional Medical Center Corporate Integrity Agreement
75. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
86. a summary of all Policies and Procedures required by Section III.B.2 III.B (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and;
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 118. a description of the Disclosure Program required by Section III.GIII.E;
9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this CIA; (d) a summary and description of any and all current and prior engagements and agreements between ▇▇▇▇▇▇▇▇▇▇ Regional and the IRO; and (e) a certification from the IRO regarding its professional independence and objectivity with respect to ▇▇▇▇▇▇▇▇▇▇ Regional;
10. a description of the process by which ▇▇▇▇▇▇▇▇▇▇ Regional fulfills the requirements of Section III.F regarding Ineligible Persons;
11. a list of all of ▇▇▇▇▇▇▇▇▇▇ Regional’s locations (including locations and mailing addresses); the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Medicare and state Medicaid program provider number and/or supplier number(s); and the name ▇▇▇▇▇▇▇▇▇▇ Regional Medical Center Corporate Integrity Agreement and address of each Medicare and state Medicaid program contractor to which ▇▇▇▇▇▇▇▇▇▇ Regional currently submits claims;
12. a description of ▇▇▇▇▇▇▇▇▇▇ Regional’s corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and
Appears in 1 contract
Sources: Corporate Integrity Agreement
Implementation Report. Within 120 150 days after the Effective Date, KDMC Spectranetics shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Chief Compliance Officer required by Section III.A.1, and a summary of other noncompliance job responsibilities the Chief Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2;
3. the names of the Board members who are responsible for satisfying the Spectranetics’ Board of Directors compliance obligations described referenced in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s Spectranetics’ Code of Conduct required by Section III.B.1;
75. a copy of all Policies and Procedures required by Section III.B.2;
6. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG OIG, upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);
97. the following information regarding each type of training required by Section III.C:
a. a description of such training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptions. Spectranetics Corporate Integrity Agreement A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 118. a description of the Disclosure Program required by Section III.GIII.E;
9. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; and (c) a summary and description of any and all current and prior engagements and agreements between Spectranetics and the IRO;
10. a certification from the IRO regarding its professional independence and objectivity with respect to Spectranetics;
11. a description of the process by which Spectranetics fulfills the requirements of Section III.F regarding Ineligible Persons;
12. the name, title, and responsibilities of any person who is determined to be an Ineligible Person under Section III.F; the actions taken in response to the screening and removal obligations set forth in Section III.F;
13. a list of all of Spectranetics’ locations (including locations and mailing addresses) at which it performs Promotional and Product Services Related Functions, Reporting Related Functions, and Clinical Investigation Related Functions; the corresponding name under which each location is doing business; the corresponding phone numbers and fax numbers; each location’s Federal health care provider number and/or supplier number(s) (if applicable); and the name and address of each Federal health care program contractor to which Spectranetics currently submits claims (if applicable);
14. a description of Spectranetics’ corporate structure, including identification of any parent and sister companies, subsidiaries, and their respective lines of business; and
Appears in 1 contract
Implementation Report. Within 120 days after the Effective Date, KDMC AtriCure, Inc. shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report). The Implementation Report shall, at a minimum, include:
1. the name, address, phone number, and position description of the Compliance Officer required by Section III.A.1III.A, and a summary of other noncompliance job responsibilities the Compliance Officer may have;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2III.A;
3. the names of the Board members who are responsible for satisfying of the Committee of the Board of Directors compliance obligations described referenced in Section III.A.3;
III.A.3 4. the names, addresses, phone numbers, names and position descriptions positions of the Physician Executive(s) Certifying Employees required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may haveIII.A.4;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMCAtriCure, Inc.’s Code of Conduct required by Section III.B.1;
6. a copy of all Policies and Procedures required by Section III.B.2;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG OIG, upon request);
8. a summary of all Policies and Procedures required by Section III.B.2 (copies of the Policies and Procedures shall be made available to OIG upon request);
9. the following information regarding each type of training required by Section III.C:
a. a description of such the initial and annual training, including a summary of the topics covered, the length of sessions, and a schedule of training sessions; andand CORPORATE INTEGRITY AGREEMENT ATRICURE, INC.
b. the number of individuals required to be trainedcomplete the initial and annual training, the percentage of individuals who actually trainedcompleted the initial and annual training, and an explanation of any exceptions. A copy of all training materials and the documentation supporting this information shall be made available to OIG OIG, upon request.
10. a description of (a) the Focus Arrangements Tracking System required by Section III.F.1.a, (b) the internal review and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 119. a description of the Disclosure Program required by Section III.GIII.E;
10. the following information regarding the IRO(s): (a) identity, address, and phone number; (b) a copy of the engagement letter; and (c) a summary and description of any and all current and prior engagements and agreements between AtriCure, Inc. and the IRO;
11. a certification from the IRO regarding its professional independence and objectivity with respect to AtriCure, Inc.;
12. a description of the process by which AtriCure, Inc. fulfills the requirements of Section III.F regarding Ineligible Persons;
Appears in 1 contract
Implementation Report. Within 120 150 days after the Effective Dateeffective date of this --------------------- CIA, KDMC Rotech shall submit a written report to OIG summarizing the status of its implementation of the requirements of this CIA (Implementation Report)CIA. The This Implementation Report shall, at a minimum, shall include:
1. the name, address, phone number, position description, and position description summary of other non-compliance job responsibilities of the Compliance Officer and Compliance Liaisons required by Section III.A.1, and a summary of other noncompliance job responsibilities the Compliance Officer may havesection III.A;
2. the names and positions of the members of the Compliance Committee required by Section III.A.2section III.A;
3. the names of the Board members who are responsible for satisfying the Board of Directors compliance obligations described in Section III.A.3;
4. the names, addresses, phone numbers, and position descriptions of the Physician Executive(s) required by Section III.A.6, and a summary of other job responsibilities that each Physician Executive may have;
5. the name, address, phone number, and position description of the Medical Director of the Cardiac Catheterization Laboratory required by Section III.A.7, and a summary of other job responsibilities the Medical Director may have;
6. a copy of KDMC’s Rotech's Code of Conduct required by Section section III.B.1, in the event it was revised pursuant to the CIA;
7. the number of individuals required to complete the Code of Conduct certification required by Section III.B.1, the percentage of individuals who have completed such certification, and an explanation of any exceptions (the documentation supporting this information shall be made available to OIG upon request);
84. a summary copy of all compliance-related Policies and Procedures required by Section section III.B.2 (copies and a summary of the all other Policies and Procedures shall be made available required by section III.B.2, in the event they were revised or newly created pursuant to OIG upon request)the CIA;
95. a representative sample of training materials used for the following information regarding each type of training required by Section section III.C:
a. , a description of such training, including a summary Rotech Corporate Integrity Agreement description of the topics coveredtargeted audiences, the length of sessions, which sessions were mandatory and for whom, percentage of attendance, and a schedule of when the training sessions; and
b. the number of individuals required to be trained, percentage of individuals actually trained, and an explanation of any exceptionssessions were held. A copy of all training materials and used for the documentation supporting this information training required by section III.C shall be made available to OIG upon request.;
106. a description of (a) certification by the Focus Arrangements Tracking System required by Section III.F.1.a, (b) Compliance Officer that:
a. the internal review Policies and approval process required by Section III.F.1.e; and (c) the tracking and monitoring procedures and other Focus Arrangements Procedures required by Section III.F.1; 11. a description section III.B have been developed, are being implemented, and have been distributed to all appropriate Covered Persons;
b. all Covered Persons have completed the Code of the Disclosure Program Conduct certification required by Section III.G;section III.B.1; and
c. all Covered Persons have completed the applicable training and executed the certification(s) required by section III.C.; The documentation supporting this certification shall be available to OIG, upon request.
Appears in 1 contract
Sources: Corporate Integrity Agreement (Rotech Healthcare Inc)